MEK and the inhibitors: From bench to bedside

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Akinleye, Akintunde ^a   Furqan, Muhammad ^a   Mukhi, Nikhil ^a   Ravella, Pavan ^a   Liu, Delong ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) N (2 HYDROXYETHOXY) 5 [(3 OXO 1,2 OXAZINAN 2 YL)METHYL]BENZAMIDE; ARRY 438162; AZD 8330; DOCETAXEL; GDC 0973; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PIMASERTIB; REFAMETINIB; RO 5126766; SELUMETINIB; TAK 733; TRAMETINIB; UNCLASSIFIED DRUG; WX 554; XL5 18;

ASTHENIA; BLURRED VISION; DERMATITIS; DIARRHEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; METASTATIC MELANOMA; NAUSEA; NONHUMAN; PROGRESSION FREE SURVIVAL; RASH; RETINOPATHY; REVIEW; TREATMENT RESPONSE; VISUAL DISORDER; XEROSTOMIA;

HUMANS; MAP KINASE KINASE 1; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84876249574     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-27     Document Type: Review

References (115)

1. Mammalian MAP kinase signalling cascades. Chang L, Karin M, Nature 2001 410 6824 37 40
2. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Thompson N, Lyons J, Curr Opin Pharmacol 2005 5 4 350 356
3. Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Hsueh C-T, Liu D, Wang H, Biomarker Res 2013 1 1 1
4. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Furqan M, Mukhi N, Lee B, Liu D, Biomarker Res 2013 1 1 5
5. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, N Engl J Med 2011 364 26 2507 2516
6. Current management and novel agents for malignant melanoma. Lee B, Mukhi N, Liu D, J Hematol Oncol 2012 5 3
7. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, Carr D, Zhu H, Wong J, Yang RS, Biochemistry 2009 48 12 2661 2674
8. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Takekawa M, Tatebayashi K, Saito H, Mol Cell 2005 18 3 295 306
9. A full-length 3D structure for MAPK/ERK kinase 2 (MEK2). Liang H, Liu T, Chen F, Liu Z, Liu S, Sci China Life Sci 2011 54 4 336 341
10. The role of scaffold proteins in MEK/ERK signalling. Sacks DB, Biochem Soc Trans 2006 34 Pt 5 833 836
11. RAS oncogenes: weaving a tumorigenic web. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D, Nat Rev Cancer 2011 11 11 761 774
12. RAF protein-serine/threonine kinases: structure and regulation. Roskoski R Jr, Biochem Biophys Res Commun 2010 399 3 313 317
13. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Roovers K, Assoian RK, Bioessays 2000 22 9 818 826
14. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR, Genes Dev 2000 14 19 2501 2514
15. Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Hwang CY, Lee C, Kwon KS, Mol Cell Biol 2009 29 12 3379 3389
16. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Nat Cell Biol 2008 10 2 138 148
17. Tumour cell survival signalling by the ERK1/2 pathway. Balmanno K, Cook SJ, Cell Death Differ 2009 16 3 368 377
18. Mutations of the BRAF gene in human cancer. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Nature 2002 417 6892 949 954
19. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Cancer Res 2008 68 14 5524 5528
20. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Murugan AK, Dong J, Xie J, Xing M, Cell Cycle 2009 8 13 2122 2124
21. Chromosomal localization of four MAPK signaling cascade genes: MEK1, MEK3, MEK4 and MEKK5. Rampoldi L, Zimbello R, Bortoluzzi S, Tiso N, Valle G, Lanfranchi G, Danieli GA, Cytogenet Cell Genet 1997 78 3-4 301 303
22. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). Han J, Lee JD, Jiang Y, Li Z, Feng L, Ulevitch RJ, J Biol Chem 1996 271 6 2886 2891
23. Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade. Stein B, Brady H, Yang MX, Young DB, Barbosa MS, J Biol Chem 1996 271 19 11427 11433
24. MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling. Virtue A, Wang H, Yang X-f, J Hematol Oncol 2012 5 1 66
25. Activation and signaling of the p38 MAP kinase pathway. Zarubin T, Han J, Cell Res 2005 15 1 11 18
26. Mechanism of p38 MAP kinase activation in vivo. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ, Genes Dev 2003 17 16 1969 1978
27. p38 MAP kinase's emerging role as a tumor suppressor. Bulavin DV, Fornace AJ Jr, Adv Cancer Res 2004 92 95 118
28. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E, Fornace AJ Jr, Nature 2001 411 6833 102 107
29. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR, Cancer 2003 97 12 3017 3026
30. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Hanks SK, Quinn AM, Hunter T, Science 1988 241 4861 42 52
31. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Kyriakis JM, Avruch J, Physiol Rev 2001 81 2 807 869
32. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF, Cell 2003 112 2 181 192
33. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Ip YT, Davis RJ, Curr Opin Cell Biol 1998 10 2 205 219
34. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche A, Maroney AC, Neuron 2003 38 6 899 914
35. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ, Science 2000 288 5467 870 874
36. Novel role for JNK as a stress-activated Bcl2 kinase. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS Jr, J Biol Chem 2001 276 26 23681 23688
37. c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal. Xu P, Davis RJ, Mol Cell Biol 2010 30 6 1329 1340
38. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, Labow MA, Zon LI, Proc Natl Acad Sci USA 1998 95 12 6881 6886
39. Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. Nishina H, Bachmann M, Oliveira-dos-Santos AJ, Kozieradzki I, Fischer KD, Odermatt B, Wakeham A, Shahinian A, Takimoto H, Bernstein A, J Exp Med 1997 186 6 941 953
40. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL, Picard M, Rosenzweig A, Force T, J Clin Invest 1999 104 4 391 398
41. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ, Science 1995 267 5198 682 685
42. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J, J Biol Chem 1996 271 30 17920 17926
43. Identification of a dual specificity kinase that activates the Jun kinases and p 38-Mpk2. Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M, Science 1995 268 5208 286 290
44. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Calhoun ES, Falco G, Abdelmohsen K, Gorospe M, Kern SE, Cancer Res 2006 66 11 5560 5564
45. Homozygous deletion of MKK4 in ovarian serous carcinoma. Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih Ie M, Wang TL, Cancer Biol Ther 2006 5 6 630 634
46. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD, Cancer Res 2006 66 4 2264 2270
47. Isolation of MEK5 and differential expression of alternatively spliced forms. English JM, Vanderbilt CA, Xu S, Marcus S, Cobb MH, J Biol Chem 1995 270 48 28897 28902
48. Components of a new human protein kinase signal transduction pathway. Zhou G, Bao ZQ, Dixon JE, J Biol Chem 1995 270 21 12665 12669
49. MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. Chao TH, Hayashi M, Tapping RI, Kato Y, Lee JD, J Biol Chem 1999 274 51 36035 36038
50. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. Kamakura S, Moriguchi T, Nishida E, J Biol Chem 1999 274 37 26563 26571
51. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD, EMBO J 1997 16 23 7054 7066
52. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. Sun W, Kesavan K, Schaefer BC, Garrington TP, Ware M, Johnson NL, Gelfand EW, Johnson GL, J Biol Chem 2001 276 7 5093 5100
53. PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation. Nakamura K, Uhlik MT, Johnson NL, Hahn KM, Johnson GL, Mol Cell Biol 2006 26 6 2065 2079
54. The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells. Akaike M, Che W, Marmarosh NL, Ohta S, Osawa M, Ding B, Berk BC, Yan C, Abe J, Mol Cell Biol 2004 24 19 8691 8704
55. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. English JM, Pearson G, Baer R, Cobb MH, J Biol Chem 1998 273 7 3854 3860
56. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Kasler HG, Victoria J, Duramad O, Winoto A, Mol Cell Biol 2000 20 22 8382 8389
57. Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Terasawa K, Okazaki K, Nishida E, Genes Cells 2003 8 3 263 273
58. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD, Nature 1998 395 6703 713 716
59. Regulation of cellular functions by the ERK5 signalling pathway. Wang X, Tournier C, Cell Signal 2006 18 6 753 760
60. Requirement of the MEK5-ERK5 pathway for neural differentiation in Xenopus embryonic development. Nishimoto S, Kusakabe M, Nishida E, EMBO Rep 2005 6 11 1064 1069
61. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K, Proc Natl Acad Sci USA 2002 99 14 9248 9253
62. Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer. Hu B, Ren D, Su D, Lin H, Xian Z, Wan X, Zhang J, Fu X, Jiang L, Diao D, BMC Cancer 2012 12 127
63. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY, Oncogene 2003 22 9 1381 1389
64. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P, Pandiella A, Mol Cell Biol 2002 22 1 270 285
65. Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, Meyer C, Rosenwald A, Drexler HG, MacLeod RA, Blood 2007 109 7 3015 3023
66. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA, Mossman BT, Am J Respir Cell Mol Biol 2008 38 2 209 217
67. Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, N Engl J Med 2012 367 2 107 114
68. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K, Curr Top Med Chem 2005 5 2 215 229
69. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T, Int J Oncol 2011 39 1 23 31
70. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Clin Cancer Res 2011 17 5 989 1000
71. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Lancet Oncol 2012 13 8 773 781
72. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Br J Haematol 2010 149 4 537 549
73. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Yoon J, Koo KH, Choi KY, Cancer Res 2011 71 2 445 453
74. Phase I/II study of FOLFIRI plus the MEK1/2 inhibitor pimasertib (MSC1936369b) as second-line treatment for kras mutated metastatic colorectal cancer. Macarulla T, Tabernero J, Cervantes A, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Campana F, Laffranchi B, Jego V, von Richter O, Ciardiello F, Ann Oncol 2012 23 Suppl 4 D-0024
75. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Clin Cancer Res 2007 13 5 1576 1583
76. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, J Clin Oncol 2008 26 13 2139 2146
77. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY, Invest New Drugs 2011 29 5 1021 1028
78. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC, Invest New Drugs 2012 30 3 1216 1223
79. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V, J Thorac Oncol 2010 5 10 1630 1636
80. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Clin Cancer Res 2012 18 7 2056 2065
81. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Clin Cancer Res 2012 18 2 555 567
82. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, J Clin Oncol 2011 29 17 2350 2356
83. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Lancet Oncol 2013 14 1 38 47
84. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Lancet Oncol 2013 14 2 134 140
85. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, N Engl J Med 2013 368 7 623 632
86. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Bioorg Med Chem Lett 2008 18 24 6501 6504
87. The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential. Sebolt-Leopold JS, Merriman R, Omer C, Tecle H, Bridges A, Klohs W, Loi C-M, Valik H, Przybranowski S, Meyer M, AACR Meeting Abstracts 2004 2004 1 925
88. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL, Mol Cancer Ther 2010 9 7 1968 1976
89. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, J Clin Oncol 2005 23 23 5281 5293
90. Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901. Sheth PR, Liu Y, Hesson T, Zhao J, Vilenchik L, Liu YH, Mayhood TW, Le HV, Biochemistry 2011 50 37 7964 7976
91. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Clin Cancer Res 2010 16 8 2450 2457
92. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM, Cancer Res 2009 69 17 6839 6847
93. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. Chang Q, Chapman MS, Miner JN, Hedley DW, BMC Cancer 2010 10 515
94. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. Gore L, Lewis K, Von Hoff DD, Weiss GJ, Ramanathan RK, Adjei AA, Dy GK, Ma WW, Clendeninn NJ, Leffingwell DP, ASCO Meeting Abstracts 2011 29 15-suppl 3007
95. A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC). Lim HY, Yen C-J, Tak W-Y, Heo J, Choi HJ, Lin C-Y, Yoon J-H, Hsu C, Rau K-M, Poon RTP, ASCO Meeting Abstracts 2012 30 15-suppl 4103
96. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O'Connell SM, Scorah N, Shi L, Wallace MB, Bioorg Med Chem Lett 2011 21 5 1315 1319
97. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Mol Cancer 2012 11 22
98. A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. Finn RS, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Anderson L, Christy-Bittel JL, ASCO Meeting Abstracts 2012 30 4-suppl 220
99. Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. Bendell JC, Papadopoulos K, Jones SF, Barrett E, Guthrie K, Kass CL, Litwiler KS, Napier C, Patnaik A, Mol Cancer Ther 2011 10 Supplement 1 243
100. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Lancet Oncol 2013 14 3 249 256
101. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodere F, Rojo F, Routier E, Guarin E, Xu ZX, Clin Cancer Res 2012 18 17 4806 4819
102. A phase I, first-in-human single ascending dose study of the MEK inhibitor WX-554 given to healthy male subjects. Mala C, Neville NG, Haindl E, Buergle M, Schmalix W, Bevan P, ASCO Meeting Abstracts 2010 28 15-suppl 13666
103. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K, Bioorg Med Chem Lett 2011 21 6 1795 1801
104. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Leijen S, Middleton MR, Tresca P, Kraeber-Bodere F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Clin Cancer Res 2012 18 17 4794 4805
105. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, Clin Cancer Res 2012 18 11 3090 3099
106. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Choo EF, Belvin M, Boggs J, Deng Y, Hoeflich KP, Ly J, Merchant M, Orr C, Plise E, Robarge K, Drug Metab Dispos 2012 40 5 919 927
107. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Cancer Res 2012 72 1 210 219
108. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. LoRusso P, Shapiro G, Pandya SS, Kwak EL, Jones C, Belvin M, Musib LC, de Crespigny A, McKenzie M, Gates MR, ASCO Meeting Abstracts 2012 30 15-suppl 2566
109. AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials. Wallace EM, Lyssikatos J, Blake JF, Marlow A, Greschuk J, Yeh TC, Callejo M, Marsh V, Poch G, Otten J, Hingorani G, Winski SL, Anderson DA, Lee P, Winkler J, Koch K, Davies BR, Jones DC, Logie A, Curtis NJ, Chresta CM, Smith PD, Robinson DT, Cancer Res 2009 AACR Annual Meeting Proceedings 2009
110. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R, Eur J Cancer 2013 49 1521 1529
111. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. Ponti G, Tomasi A, Pellacani G, J Hematol Oncol 2012 5 1 60
112. Polo-like kinase 1 as target for cancer therapy. WeiSZ L, Efferth T, Exp Hematol Oncol 2012 1 1 38
113. Current management and prognostic features for gastrointestinal stromal tumor (GIST). Lamba G, Gupta R, Lee B, Ambrale S, Liu D, Exp Hematol Oncol 2012 1 1 14
114. Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors. Faulkner N, LoRusso PM, Guthrie T, Soria J-C, Bahleda R, Bendell JC, Infante JR, Massard C, Van Leeuwen B, Martini J-F, Mol Cancer Ther 2009 8 Supplement 1 197
115. Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results. Infante JR, Patnaik A, Jones SF, Papadopoulos KP, Bendell JC, Rasco DW, Bellew KM, Cox DS, Durante MG, Park JJ, Mol Cancer Ther 2011 10 Supplement 1 128